FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $815,202 | -43.9% | 171,261 | -32.8% | 0.04% | -51.1% |
| Q1 2023 | $1,453,437 | +1187.2% | 254,989 | +2178.5% | 0.09% | +1185.7% |
| Q4 2022 | $112,917 | -54.1% | 11,191 | +2.1% | 0.01% | -61.1% |
| Q3 2022 | $246,000 | -10.9% | 10,962 | -1.7% | 0.02% | 0.0% |
| Q2 2022 | $276,000 | -43.1% | 11,154 | -10.8% | 0.02% | -10.0% |
| Q1 2022 | $485,000 | -40.4% | 12,511 | -10.1% | 0.02% | -25.9% |
| Q4 2021 | $814,000 | -11.3% | 13,911 | -10.2% | 0.03% | -12.9% |
| Q3 2021 | $918,000 | +350.0% | 15,495 | +558.2% | 0.03% | +342.9% |
| Q2 2021 | $204,000 | – | 2,354 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |